Skip to main content
Premium Trial:

Request an Annual Quote

Biodesix Targets $20M Series D Round

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Biodesix has closed on the first of two tranches of a financing round targeting $20 million, a company spokesman confirmed today.

The Broomfield, Colo.-based companion diagnostics firm declined to provide details about the tranches, but in a document filed with the US Securities and Exchange Commission, Biodesix said that to date, it has raised $10 million in the round. The offering is in the form of equity.

In an e-mail to GenomeWeb Daily News, the spokesman said the round is a Series D financing, and proceeds will be used to support commercialization of its VeriStrat proteomic test to guide physicians treating patients with non-small cell lung cancer.

The funds will also support collaborations with biotechnology and pharmaceutical companies, he added. In January, a company official told GWDN that Biodesix would pursue collaborations with pharma firms to increase adoption of the test.

Participants in the round include existing investors.

The current funding follows a Series C financing round that the company completed in November that raised $7.1 million to further develop the VeriStrat test.

Biodesix plans to pursue clearance from the US Food and Drug Administration for the test, which is performed in Biodesix's CLIA laboratory. In March VeriStrat received certification from the New York State Department of Health, making it available in all 50 states.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.